학술논문
748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
Document Type
article
Author
Source
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Subject
Language
English
ISSN
2051-1426